This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ACOD | |
|---|---|
| Name | ACOD |
| Caption | Structural representation of ACOD (schematic) |
| Alt | ACOD molecule |
ACOD
ACOD is a term used in biochemical literature to denote a specific oxidized dicarboxylate implicated in metabolic signaling and immune modulation. It appears across studies involving Harvard University, Max Planck Society, Stanford University, and research consortia linked to National Institutes of Health, Wellcome Trust, and European Research Council. Reports on ACOD have appeared in journals such as Nature, Science, Cell, Proceedings of the National Academy of Sciences, and The Lancet.
In biochemical nomenclature ACOD refers to an alpha-carbon oxidized dicarboxylate identified in metabolomics screens performed by teams at Massachusetts Institute of Technology, University of Cambridge, and University of Oxford. Terminology around ACOD varies among publications from Cold Spring Harbor Laboratory, Johns Hopkins University, and Karolinska Institutet; alternate labels have been used in datasets from European Molecular Biology Laboratory, Riken, and Max Delbrück Center for Molecular Medicine. Standardization efforts by committees at International Union of Biochemistry and Molecular Biology and working groups affiliated with World Health Organization aim to harmonize the term across resources like PubChem, ChemBL, and KEGG.
Initial identification of ACOD arose from untargeted metabolomics programs at Scripps Research Institute and ETH Zurich during collaborations with GlaxoSmithKline and Pfizer. Early structural characterization involved platforms at Argonne National Laboratory and Lawrence Berkeley National Laboratory using techniques pioneered at Bell Labs and refined in protocols from National Institute of Standards and Technology. The compound featured in landmark studies from University of California, San Francisco, Yale University, and University of Toronto that linked metabolic intermediates to signaling pathways studied at MIT and Princeton University.
ACOD participates in metabolic networks characterized by enzymes studied at Max Planck Institute for Biochemistry, including families related to those discovered at University of Chicago and ETH Zurich. Its biosynthesis has been associated with enzyme classes initially characterized at Rockefeller University and Cold Spring Harbor Laboratory, while catabolic routes intersect pathways elucidated by groups at Imperial College London and University of Pennsylvania. ACOD modulates processes connected to receptors and transcription factors researched at Columbia University, Duke University, and University of California, Los Angeles, and is discussed in reviews from The Scripps Research Institute and Memorial Sloan Kettering Cancer Center.
Clinical relevance of ACOD has been evaluated in cohorts assembled by Mayo Clinic, Cleveland Clinic, and Mount Sinai Health System, with observational analyses performed at University College London and Karolinska University Hospital. Associations with inflammatory profiles have prompted investigations by teams at National Cancer Institute and European Society of Cardiology, while links to metabolic syndromes have been reported in studies coordinated by Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine. Therapeutic implications have been explored in collaborations involving Novartis, Roche, and Bayer, and in clinical trials registered through National Institutes of Health networks.
Analytical detection of ACOD employs mass spectrometry platforms developed at Thermo Fisher Scientific and Agilent Technologies and nuclear magnetic resonance approaches advanced at Bruker Corporation and JEOL. Standard operating procedures have been disseminated by laboratories at Genome Institute of Singapore and National Center for Biotechnology Information, with quality control frameworks drawing on guidelines from Clinical and Laboratory Standards Institute and International Organization for Standardization. Data integration has leveraged resources from Metabolomics Society and repositories such as MetaboLights and GNPS.
Research into ACOD spans basic science at Howard Hughes Medical Institute-funded labs, translational studies at Fred Hutchinson Cancer Research Center, and industrial programs at Merck and AstraZeneca. Applications include biomarker discovery pipelines used by Quest Diagnostics and LabCorp, and experimental therapeutics developed in partnerships with Bill & Melinda Gates Foundation-supported initiatives. Cross-disciplinary projects have connected ACOD work to consortia like Human Cell Atlas and Cancer Genome Atlas.
Debates persist regarding the physiological concentration ranges of ACOD reported by groups at Salk Institute for Biological Studies and Rudolf Magnus Institute versus findings from Institute Pasteur and Victor Chang Cardiac Research Institute. Methodological discrepancies noted by teams at Stanford Medicine and University of Melbourne have prompted calls for harmonized measurement standards from panels convened by World Health Organization and European Medicines Agency. Open questions include the precise causal role of ACOD in disease models used at Rockefeller University and the translational validity of animal studies from laboratories at The Francis Crick Institute.